Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09LKU
|
|||
| Former ID |
DIB009635
|
|||
| Drug Name |
NOX-E36
|
|||
| Synonyms |
Monocyte chemoattractant protein-1 ligand inhibitor(spiegelmer, diabetic complications), NOXXON; MCP-1 inhibitor (spiegelmer/injectable, diabetic complications/diabetic nephropathy), NOXXON
Click to Show/Hide
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-10: E08-E13] | Phase 2 | [1] | |
| Company |
NOXXON Pharma AG
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01547897) NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria. U.S. National Institutes of Health. | |||
| REF 2 | Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.